Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dronedarone advisory committee review

Executive Summary

FDA's Cardiovascular and Renal Drugs Advisory Committee is meeting March 18 to discuss Sanofi-Aventis' NDA for Multaq (dronedarone) 400 mg oral tablets, proposed for patients with a history of, or current, atrial fibrillation or atrial flutter, for the reduction of the risk of cardiovascular hospitalization or death. The NDA is based on the recently published ATHENA study (1"The Pink Sheet" DAILY, Aug. 11, 2008)

You may also be interested in...



Sanofi-Aventis Gets Priority Review For Second-Generation Atrial Fib Drug

Approval could come in early 2009 for Cordarone successor Multaq.

Execs On The Move: Promotions At Agilent And CHF Solutions; New Chief At Zimmer

CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.

Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US

Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel